If you are a member of the Direct Purchaser Settlement Class, your legal rights will be affected whether you act or don’t act. Please read the Notice and/or Settlement Agreement carefully.

The information on this website is only a summary of the terms of the Settlement.

• A settlement (“Settlement”) has been reached in a class action lawsuit with Pfizer, Inc., King Pharmaceuticals, Inc. (n/k/a King Pharmaceuticals LLC), and Meridian Medical Technologies, Inc. (collectively, “Pfizer”). Under the Settlement, Pfizer agreed to pay $50,000,000 into a settlement fund (“Settlement Fund”) for the Direct Purchaser Settlement Class. The Settlement is only with Pfizer and resolves only the claims against Pfizer.

• The lawsuit alleges that Defendants Mylan, N.V., Mylan Pharmaceuticals, Inc., and Mylan Specialty, LP (collectively, “Mylan”), and Pfizer entered into an illegal market allocation agreement with Teva Pharmaceuticals USA, Inc. (“Teva”) that substantially delayed the launch of generic EpiPen and unlawfully extended Pfizer’s and Mylan’s monopoly over the epinephrine autoinjector market.

• The Court granted Final Approval of the Settlement with Pfizer on July 9, 2024. A copy of this order can be viewed here.

• The deadlines to submit a claim, request exclusion, or object to the Settlement have passed.

Your legal rights are affected whether you act or don’t act. Please read carefully.

This website and the Notice summarize the Settlement. In the event of any inconsistency between the notice and the terms of the Settlement, the terms of the Settlement Agreement will control. For more details regarding this Settlement, please reference the Settlement Agreement and/or other documents filed in the case under the “Court Documents” link above. You may also contact the Settlement Administrator for further information regarding this Settlement.